Ulcerative colitis (UC) is a chronic idiopathic inflammatory disease of the gastrointestinal tract that affects the mucosal lining of the colon.
Professor Jean-Frédéric Colombel and colleagues from Portugal reviewed new therapies for ulcerative colitis.
Recent epidemiological data show that its incidence and prevalence are increasing in many parts of the world, in parallel with altered lifestyles, improved access to health, improved sanitation and industrialisation rates.
Current therapeutic strategies for treating ulcerative colitis have only been moderately successful.
|Less than half of all patients achieve long-term remission|
Despite major recent advances in inflammatory bowel disease therapeutic resources, a considerable proportion of patients are still refractory to conventional treatment.
The team noted that less than half of all patients achieve long-term remission, many require colectomy, and the disease still has a major impact on patients’ lives.
Recent data point to slightly raised mortality. While these outcomes could be partly improved by optimising current therapeutic strategies, they clearly highlight the need to develop new therapies.
The researchers report that currently, a number of promising and innovative therapeutic approaches are being explored, some of which will hopefully survive to reach the clinic.
Professor Colombel's team concludes, "Until such a time arrives, it is important that a better understanding of the clinical particularities of the disease is obtained."
"In addition, an improved knowledge of the host-microbiome negative interactions and of the environmental factors beyond disease development is required to obtain the final and desired outcome, to provide better treatment and quality of life for patients with this disabling disease."